TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: mean adjusted cost difference
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patient and surgeon satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Duration of analgesia and motor block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean SERT occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ulcer and erosion healing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Plasma potassium concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: measurable improvement of culprit lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: substantial improvement of culprit lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: treatment encounters for squamous cell carcinoma
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: treatment and dermatologic costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Risk of developing dementia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: CDR sum of boxes scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Delay recall improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in hemoglobin A(1c) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to resumption of oral soft diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of prolonged post-operative ileus
Endpoint domain: Adverse events/effects
Primary endpoint: Verbal episodic memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Set-shifting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSV (Peak Systolic Velocity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improved efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Less toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: change in OH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: renal creatinine and urea clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Resolution of urinary tract infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Improvement in voiding problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom-free status in bowel dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of incident, symptomatic BPH
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of acute adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Age at onset of puberty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean IPSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Lactate Level at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left Ventricular Ejection Fraction (LVEF) at 24, 48, and 72 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stroke Volume (SV) at 24, 48, and 72 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Salivary S. mutans counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: DeltaTC reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 1RM with HG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytokine levels (IL-6 and IL-8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Spreadability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative incisional hernia
Endpoint domain: Adverse events/effects
Primary endpoint: Fibrin generation and degradation as expressed by D-dimer fibrin split products
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rates of change in baseline brachial artery diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rates of change in maximal brachial artery diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Contrast Induced Nephropathy (CIN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cumulative in-hospital clinical complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median survival after crossover
Endpoint domain: Mortality/survival
Primary endpoint: Median PSA progression-free survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feelings of fullness and satiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Effect of treatment on emotions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of Hyperuricemia (HUA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Non-Valvular Atrial Fibrillation (NVAF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of orofacial pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: resting SBP improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sternal separation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain during everyday tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in score on the Yale‐Brown Obsessive Compulsive Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of responders on the Clinical Global Impressions scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AF recurrence in the 3 months after ablation
Endpoint domain: Mortality/survival
Primary endpoint: Complete stone-free rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average decrease in hemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time constant for O2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady-state value for O2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anal pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incontinence of faeces
Endpoint domain: Adverse events/effects
Primary endpoint: anal strictures
Endpoint domain: Adverse events/effects
Primary endpoint: recurrent arrhythmia or sudden death
Endpoint domain: Mortality/survival
Primary endpoint: Fibrinogen concentrations at hospital discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: brain amyloid deposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cardiometabolic risk composite scores (CRCSs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean CMT changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cement thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in narrative skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost per pressure ulcer avoided
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Net monetary benefit per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Clinical cure rates at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrences at 6, 9, and 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumour clearance at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: time normalization of stooling patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: one-year relapse rate
Endpoint domain: Mortality/survival
Primary endpoint: number of actions ordered
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: perceived benefit (probability of survival)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rates of severe and/or multiple complications
Endpoint domain: Adverse events/effects
Primary endpoint: pain with the first step in the morning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: function after final treatment and at 90-day follow up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone metastasis-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Time to first bone metastasis
Endpoint domain: Mortality/survival
Primary endpoint: Intraocular Lens (IOL) Decentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crying during venipuncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sedation score (crying or anxious)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Venipuncture score (crying or withdrawing)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy in predicting EOC from benign ovarian tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the ROC curve (AUC) for predicting clinical stages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival among early-stage EOC patients
Endpoint domain: Mortality/survival
Primary endpoint: ARC definite ST events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: GUSTO moderate/severe bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Miss rate of polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvements in visual functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreases in bacterial growth and adhesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival extension (mean of 4.4 months)
Endpoint domain: Mortality/survival
Primary endpoint: Low fruit and vegetable consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Mini-Mental State Examination (3MSE) score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean peak T(C) postexercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak T(C) cooling rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic Prostatitis Symptom Index scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in free androgen index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Increased chance of menstrual regularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disruption of vitreous attachment to ILM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amounts of LN and FN in the ILM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal cell viability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: myoFSR change after WHEY
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: decrease in nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of HFC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of obsessive-compulsive disorder (OCD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Mental health outcomes
Primary endpoint: Tolerance of ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Extent of electrocardiographic signs of ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Coronary Sinus Blood Flow (CBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients with well-controlled asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abiraterone exposure (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMI Z‐score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of subcutaneous fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BESS performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 48 hr morphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CPIP (Chronic Pulmonary Insufficiency of Prematurity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prescribing rates of Long‐Acting Reversible Contraception (LARC)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adequate clinical and parasitological responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum triglyceride level reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma ET-1 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma NO concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nonsurvival prediction
Endpoint domain: Mortality/survival
Primary endpoint: New moderate/big problem with passing stools
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Propofol dose required
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum urinary flow changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: severity of symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Bronchial hyperresponsiveness to metacholine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prevalence of Metabolic Syndrome (MeS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: solution deposition pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: macroscopic scars' appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: old scars' thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: reduction in affected limb volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in extracellular fluid index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: softening of tissues in the affected upper arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of venous insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of varicose veins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: worsening of respiratory allergic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: seizure duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: times to start of spontaneous respiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentrations of Faecalibacterium prausnitzii
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Concentrations of Bacteroides-Prevotella
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of esophageal mucosal injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: carotid territory stroke
Endpoint domain: Mortality/survival
Primary endpoint: CD4+ T-cell declines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: self-stigma for seeking help
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: help-seeking behavior from new sources
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: serum TG level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: percent change in serum TG level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PCDAI score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anal fissure epithelialization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fistula obliteration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary CTGF levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall success rate for retrograde ureteroscopy and laser lithotripsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: success rate for the first ESWL session
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: FAEQ for successful treatments
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: spontaneous loss of pregnancy
Endpoint domain: Mortality/survival
Primary endpoint: completed miscarriage loss
Endpoint domain: Mortality/survival
Primary endpoint: plasma levels of 6-keto-prostaglandin F1alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: plasma prostaglandin E2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: renin release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: pH of umbilical arterial blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response Rate (RR) to CRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in haemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: increase in mean serum ferritin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: percentage of mothers with ferritin levels below 30 microg/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Behavioral outcomes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Academic outcomes
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in coronary artery calcium volume score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in risky choice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HDRS-17 score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-oral fat load peaks of lipid-traffic adipocytokines and inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cost effectiveness of instructional methods
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time efficiency in student learning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mixed venous saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Greater than 50% restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mean average change in best-corrected visual acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elevated intraocular pressure (IOP)
Endpoint domain: Adverse events/effects
Primary endpoint: Intake of low-fat cheese
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intake of fish
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maternal fasting glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fecal levels of polyamines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Colonization with lactobacilli and bifidobacterium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Colonization with S. aureus and Enterobacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes